The HRT story after 2024

What the WHI re-analyses changed, and how to think about the conversation at 47, 52, and 60.

The 2002 Women's Health Initiative paper changed how an entire generation of women thought about hormone replacement therapy. The risk-benefit ratio it reported — specifically the increased breast cancer signal — took HRT out of mainstream medicine almost overnight.

What the original paper undersold: the women enrolled averaged 63 years old, more than a decade past menopause. The HRT formulation used (conjugated equine estrogens + medroxyprogesterone acetate) is not what current clinical practice prescribes. The cardiovascular signal that drove the headlines was largely confined to the older cohort.

What changed in the re-analyses

Subsequent re-analyses stratified by age. For women who started HRT within 10 years of menopause onset, the cardiovascular benefit became measurable. For breast cancer, the absolute risk increase remained but proportional to baseline risk and substantially smaller than the relative-risk headline suggested.

The current Endocrine Society position (and the British Menopause Society, and NAMS) is that HRT in early postmenopause — within 10 years of last period and under age 60 — is appropriate symptom management with a favourable risk profile for the average woman.

What this means for your conversation

• If you are 47 and in peri: HRT is on the table, with low-dose transdermal estradiol being the cleanest starting point per current guidance.
• If you are 52 and 3 years post-period: still in the favourable window.
• If you are 60+ and never started: the "timing hypothesis" suggests starting now carries more risk than starting earlier would have.

Questions to bring to your clinician

• What is my personal absolute baseline risk for breast cancer, CVD, and osteoporotic fracture?
• Transdermal vs oral estradiol — which is appropriate for me and why?
• Micronised progesterone vs synthetic progestin?
• What's my plan to re-assess at 1 year, 3 years, 5 years?

This is a starting frame, not medical advice. Take it to a clinician who has actually read the post-2017 literature.